Abstract
Novartis was created in 1996 from the merger of the Swiss companies, Ciba and
Sandoz. This report provides a full review of the company's activities
together with sales forecasts for key products to 2010.
Following the merger of Ciba and Sandoz, the spin-off of the Agribusiness
sector and the sale of the remaining activities of the Industry division,
Novartis has become a leading company in the life sciences field. Novartis is
currently organised into the three divisions of Pharmaceuticals, Consumer
Health and Sandoz. A fourth division, Vaccines & Diagnostics, will be created
after the acquisition of Chiron Corporation.
Current Growth Drivers
These include: Diovan (valsartan), Glivec/Gleevec (imatinib), Zelmac/Zelnorm
(tegaserod), Femara (letrozole) and Zometa (zoledronate).
Key Late-Phase Products Reaching the Market
- Lucentis (ranibizumab) is currently filed for age-related macular
degeneration.
- Two cardiovascular products currently filed have the potential to become
mega-blockbusters: Rasilez (aliskiren) for the treatment of hypertension; and
Galvus (vildagliptin), indicated for Type II diabetes.
View Cart
